| TOP STORY | T Cells Outpace Virus by Getting a Jump-Start on Division Killer T cells begin to divide en route to virus-infected tissue, allowing them to hit the ground running when they arrive, according to a study. [Press release from EurekAlert! discussing online prepublication in the Journal of Experimental Medicine] |
| SCIENCE NEWS | UCSF Team Discovers New Way to Predict Breast Cancer Survival and Enhance Effectiveness of Treatment A team of researchers has discovered a new way to predict breast cancer survival based on an “immune profile” – the relative levels of three types of immune cells within a tumor. [Press release from the University of California, San Francisco (UCSF) discussing online prepublication in Cancer Discovery] Karmanos Researchers Couple Tumor Cryoablation with Immunotherapy to Improve Tumor Immunity Scientists presented data at the American Association for Cancer Research’s (AACR) 102nd Annual Meeting 2011 showing that when tumor cryoablation is coupled with immune system modulation, the procedures have the potential to initiate or amplify tumor immunity. [Press release from the Barbara Ann Karmanos Cancer Institute in Detroit discussing data presented at AACR 2011] Clinical Trial Success for Crohn’s Disease Cell Therapy Researchers have used patient’s own immune system cells derived from peripheral blood mononuclear cells to treat patients with chronic inflammatory diseases like Crohn’s disease. [Press release from EurekAlert! discussing research presented at the UK National Stem Cell Network 2011 Annual Science Conference] Immune System May Guide Chemotherapy for Breast Cancer A study showed how evaluating the immune response in the tumor microenvironment may help researchers better target therapy in breast cancer. [Press release from the American Association for Cancer Research (AACR) discussing research presented at the AACR 102nd Annual Meeting 2011] |
| INDUSTRY NEWS | Walk Away with a RoboSep™ Facebook Photo Contest Winners STEMCELL Technologies has announced the Grand Prize Winner and Finalists of the “Walk Away With A RoboSep™” Facebook photo contest. [STEMCELL Technologies Inc. Press Release] Fred Hutchinson Cancer Research Center to Lead Immunotherapy Clinical Trials Network Research institutions at 27 sites in the U.S. and Canada have been selected to participate in the Cancer Immunotherapy Trials Network, a new initiative in immunotherapy funded by the National Cancer Institute and headquartered at Fred Hutchinson Cancer Research Center. [Fred Hutchinson Cancer Research Center Press Release] Immunomedics Presents New DNL-Derived Antibodies for Mantle Cell Lymphoma at AACR Annual Meeting Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, reported the development of 2 new antibodies produced by the Company’s proprietary Dock-and-Lock (DNL) technology for the potential treatment of mantle cell lymphoma (MCL) and other B-cell lymphomas. [GlobeNewswire] TxCell Receives Approval for a Phase I/II Clinical Trial in Rheumatoid Arthritis TxCell SA, a biotechnology company developing cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high unmet medical need, announces the approval by AFSSAPS, the French regulatory agency, of its application to carry out a phase I/II clinical trial of its second product candidate, TX-RAD. [TxCell SA Press Release] MediImmune, Inserm and Inserm Transfert Announce Strategic Collaboration to Fund and Conduct Medical Science Research MedImmune, the global biologics business of AstraZeneca, and Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (Inserm), announced a three-year strategic collaboration to advance research across a range of therapeutic areas including oncology, respiratory, inflammation, and autoimmune diseases. [MedImmune Press Release] Idera Pharmaceuticals Presents Data from a Multiple-Dose Phase 1 Clinical Trial of IMO-3100, Lead Drug Candidate for the Treatment of Autoimmune Diseases Idera Pharmaceuticals, Inc. announced the presentation of data from its multiple-dose Phase 1 clinical trial of IMO-3100 in healthy subjects. [Idera Pharmaceuticals, Inc. Press Release] W. M. Keck Foundation Awards $1 Million to Hutchinson Center to Study How Environmental Exposures Lead to Disease A $1 million grant from W.M. Keck Foundation will allow researchers at Fred Hutchinson Cancer Research Center to pursue an ambitious project to sequence DNA from the human immune system to shed light on the genetic signatures of a large number of pathogenic exposures, starting with 17 common viruses and bacteria. [Fred Hutchinson Cancer Research Center Press Release] |
|
|
|